Table 3. Summary of clinical responses.
|
Panobinostat dose |
Overall | ||||
|---|---|---|---|---|---|
| 10 mg | 20 mg | 30 mg | 40 mg | ||
| AML (n=29) | |||||
| CR/CRi | 1 | 1 | 1 | 3 (10%) | |
| PR | 1 | 1 | 4 | 6 (21%) | |
| Overall (CR/CRi/PR) | 9 (31%) | ||||
| Resistant | 4 | 8 | 2 | 14 (48%) | |
| Not evaluable | 4 | 2 | 6 (21%) | ||
| MDS (n=10) | |||||
| CR | 1 | 1 | 2 (20%) | ||
| Marrow CR (mCR) | 1 | 1 | 2 (20%) | ||
| PR | 1 | 1 (10%) | |||
| Overall (CR/mCR/PR) | 5 (50%) | ||||
| Stable disease | 1 | 1 (10%) | |||
| Progressive disease | 1 | 2 | 3 (30%) | ||
| Not evaluable | 1 | 1 (10%) | |||
| % Major hematologic improvement | |||||
| HI-Erythroid | 1 | 1 | 1 | 3/9 (30%) | |
| HI-Platelet | 1 | 1/5 (20%) | |||
| HI-Neutrophil | 2 | 2/2 (100%) | |||
Abbreviations: AML, acute myeloid leukemia; CR, complete remission; CRi, complete remission with incomplete blood count recovery; HI, hematological improvement; MDS, myelodysplastic syndrome; PR, partial remission.